Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving ...
Today1d
Jill Martin raises awareness of genetic testing for breast cancer on Football Night in America
Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...
News Medical2d
Novel bladder cancer treatment gains MHRA approval in the UK
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...
MedPage Today3d
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...
Cure Today3d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
PharmiWeb4d
MHRA grants marketing authorisation to J&J’s bladder cancer therapy BALVERSA® (erdafitinib)
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...
Cancer Therapy Advisor4d
Pembrolizumab Shows Consistent Activity in Platinum-Ineligible Urothelial Carcinoma
First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...